John A. Stalfort III - Jun 30, 2021 Form 3/A - Amendment Insider Report for Acumen Pharmaceuticals, Inc. (ABOS)

Role
Director
Signature
/s/ Katherine Denby, Attorney-in-Fact
Stock symbol
ABOS
Transactions as of
Jun 30, 2021
Transactions value $
$0
Form type
3/A - Amendment
Date filed
7/8/2021, 05:59 PM
Date Of Original Report
Jun 30, 2021
Next filing
Jul 8, 2021

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding ABOS Series B Preferred Jun 30, 2021 Common Stock 132K See footnote F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each share of Series B Preferred Stock will automatically convert into the same number of shares of Common Stock of the Issuer upon the closing of the Issuer's initial public offering. The Series B Preferred Stock has no expiration date.
F2 These shares were omitted from the reporting person's original Form 3.
F3 The securities are held by Gineane Holly Stalfort, as Trustee of the John A. Stalfort III 2018 Irrevocable Trust under agreement dated as of October 25, 2018.